Table 1:
Sociodemographic, inflammatory marker, and clinical characteristics of the study sample reported as mean (standard deviation) unless where reported as a percentage (n=37).
| Baseline | 6-month follow up | 12-month follow up | |
|---|---|---|---|
| Sex (% male) | 62.2% | ||
| Age (years) | 19.76 (4.69) | ||
| Race (% white) | 56.8% | ||
| SOPS Negative Symptom Total Score | 10.70 (6.11) | 8.49 (5.40) | 7.86 (5.28) |
| N1: Social Isolation or Withdrawal | 1.95 (1.62) | 1.73 (1.54) | 1.73 (1.22) |
| N2: Avolition | 2.03 (1.59) | 1.57 (1.24) | 1.68 (1.53) |
| N3: Decreased Expression of Emotion | 1.30 (1.37) | 1.24 (1.50) | 0.95 (1.15) |
| N4: Decreased Experience of Emotions and Self | 1.81 (1.70) | 1.14 (1.42) | 0.97 (1.36) |
| N5: Decreased Ideational Richness | 1.11 (1.33) | 1.03 (1.32) | 0.73 (0.99) |
| N6: Deterioration in Role Functioning | 2.51 (1.94) | 1.78 (1.81) | 1.81 (2.12) |
| CDSS | 5.14 (4.50) | 3.67 (3.42)* | 3.27 (3.24) |
| IL-1beta | 0.0363 (1.05) | ||
| IL-6 | 0.6062 (1.26) | ||
| TNF | −0.1653 (0.35) | ||
| IFN-gamma** | 0.1248 (0.95) | ||
| IL-10* | 0.0714 (0.86) | ||
| IL-1RA | 0.5665 (0.95) | ||
| IL-8* | 0.1626 (0.99) | ||
| IL-4 | 0.9865 (1.81) |
CDSS: Calgary Depression Scale for Schizophrenia; IL-1beta: interleukin 1 beta; IL-6: interleukin 6; TNF: tumor necrosis factor; IFN-gamma: interferon gamma; IL-10: interleukin 10; IL-1RA: interleukin 1 receptor antagonist; IL-8: interleukin 8; IL-4: interleukin 4.
*
n=36
**
n=35